Gene targeting with AAV vectors for the treatment of Osteogenesis Imperfecta View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2008-2013

FUNDING AMOUNT

657605 USD

ABSTRACT

DESCRIPTION (provided by applicant): This proposal describes a five-year training program to develop an academic career in Medical Genetics and gene therapy. The program will further advance the investigator's research in the development of an AAV-mediated gene targeting strategy for the treatment of Osteogenesis Imperfecta. The investigator will be mentored by Dr. David Russell, well recognized for his achievements in developing the adeno-associated virus (AAV) vector system for gene targeting. Osteogenesis Imperfecta (01) is a group of inherited collagen disorders characterized by bone fragility with clinical manifestations varying from a mild increase in fractures to severe bone deformities and death. Mutations that cause Ol are located in the COL1A1 and COL1A2 genes. Current treatment options are limited and do not alleviate the complications seen in Ol. Most gene therapy systems involve the process of gene addition, where a promoter and a gene are delivered into a cell and integrate randomly. In contrast, gene targeting uses homologous sequences to alter the cell's endogenous genes in a site specific manner. By this method mutated genes can be either knocked-out or corrected. The major advantage of gene targeting is that genes can be modified at their proper location on the chromosme without disrupting cellular gene regulation. Previous work by Dr. Russell has demonstrated that an AAV-mediated gene targeting vector can target the COL1A1 gene and disrupt dominant negative mutant procollagen production. It was shown that the loss of the mutant protein improved the processing, stability and structure of the collagen fibril. The objective of this proposal is to develop an AAV gene targeting vector that will target the COL1A2 gene, reduce random integration, and target multiple individuals with Ol. The specific aims include: 1) Develop an AAV gene-targeting vector to target the COL1A2 gene in Ol; 2) Develop an improved AAV gene-targeting vector to reduce the recovery of random integrants; and 3) Determine the effects of human variation on gene targeting. The completion of this project and the training received at the University of Washington will prepare the principle investigator to be a leading researcher in gene therapy. More... »

URL

http://projectreporter.nih.gov/project_info_description.cfm?aid=8315912

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2210", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "amount": {
      "currency": "USD", 
      "type": "MonetaryAmount", 
      "value": "657605"
    }, 
    "description": "DESCRIPTION (provided by applicant): This proposal describes a five-year training program to develop an academic career in Medical Genetics and gene therapy. The program will further advance the investigator's research in the development of an AAV-mediated gene targeting strategy for the treatment of Osteogenesis Imperfecta. The investigator will be mentored by Dr. David Russell, well recognized for his achievements in developing the adeno-associated virus (AAV) vector system for gene targeting. Osteogenesis Imperfecta (01) is a group of inherited collagen disorders characterized by bone fragility with clinical manifestations varying from a mild increase in fractures to severe bone deformities and death. Mutations that cause Ol are located in the COL1A1 and COL1A2 genes. Current treatment options are limited and do not alleviate the complications seen in Ol. Most gene therapy systems involve the process of gene addition, where a promoter and a gene are delivered into a cell and integrate randomly. In contrast, gene targeting uses homologous sequences to alter the cell's endogenous genes in a site specific manner. By this method mutated genes can be either knocked-out or corrected. The major advantage of gene targeting is that genes can be modified at their proper location on the chromosme without disrupting cellular gene regulation. Previous work by Dr. Russell has demonstrated that an AAV-mediated gene targeting vector can target the COL1A1 gene and disrupt dominant negative mutant procollagen production. It was shown that the loss of the mutant protein improved the processing, stability and structure of the collagen fibril. The objective of this proposal is to develop an AAV gene targeting vector that will target the COL1A2 gene, reduce random integration, and target multiple individuals with Ol. The specific aims include: 1) Develop an AAV gene-targeting vector to target the COL1A2 gene in Ol; 2) Develop an improved AAV gene-targeting vector to reduce the recovery of random integrants; and 3) Determine the effects of human variation on gene targeting. The completion of this project and the training received at the University of Washington will prepare the principle investigator to be a leading researcher in gene therapy.", 
    "endDate": "2013-12-31T00:00:00Z", 
    "funder": {
      "id": "https://www.grid.ac/institutes/grid.420086.8", 
      "type": "Organization"
    }, 
    "id": "sg:grant.2410583", 
    "identifier": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "2410583"
        ]
      }, 
      {
        "name": "nih_id", 
        "type": "PropertyValue", 
        "value": [
          "K08AR053917"
        ]
      }
    ], 
    "inLanguage": [
      "en"
    ], 
    "keywords": [
      "applicants", 
      "specific aim", 
      "fracture", 
      "death", 
      "Dr. Russell", 
      "complications", 
      "gene therapy", 
      "multiple individuals", 
      "COL1A2 gene", 
      "Dr. David Russell", 
      "description", 
      "strategies", 
      "random integrants", 
      "promoter", 
      "OL", 
      "COL1A1", 
      "training", 
      "random integration", 
      "genes", 
      "groups", 
      "mutant proteins", 
      "osteogenesis imperfecta", 
      "Washington", 
      "University", 
      "Medical Genetics", 
      "treatment", 
      "previous work", 
      "improved AAV gene", 
      "collagen fibrils", 
      "METHODS", 
      "cells", 
      "OBJECTIVE", 
      "dominant negative mutant procollagen production", 
      "sites", 
      "principle investigator", 
      "recovery", 
      "process", 
      "collagen disorders", 
      "stability", 
      "specific manner", 
      "gene targeting", 
      "mild increase", 
      "academic career", 
      "loss", 
      "proper location", 
      "five-year training program", 
      "AAV vectors", 
      "major advantage", 
      "researchers", 
      "vector system", 
      "contrast", 
      "bone fragility", 
      "cellular gene regulation", 
      "homologous sequences", 
      "investigator's research", 
      "virus", 
      "human variation", 
      "project", 
      "completion", 
      "US", 
      "development", 
      "COL1A1 gene", 
      "current treatment options", 
      "program", 
      "AAV genes", 
      "adeno", 
      "Most gene therapy systems", 
      "structure", 
      "achievement", 
      "processing", 
      "AAV", 
      "investigators", 
      "proposal", 
      "endogenous genes", 
      "chromosmes", 
      "clinical manifestations", 
      "severe bone deformities", 
      "vector", 
      "effect", 
      "gene addition", 
      "mutations"
    ], 
    "name": "Gene targeting with AAV vectors for the treatment of Osteogenesis Imperfecta", 
    "recipient": [
      {
        "id": "https://www.grid.ac/institutes/grid.66875.3a", 
        "type": "Organization"
      }, 
      {
        "affiliation": {
          "id": "https://www.grid.ac/institutes/grid.66875.3a", 
          "name": "MAYO CLINIC ROCHESTER", 
          "type": "Organization"
        }, 
        "familyName": "DEYLE", 
        "givenName": "DAVID R", 
        "id": "sg:person.01202462577.23", 
        "type": "Person"
      }, 
      {
        "member": "sg:person.01202462577.23", 
        "roleName": "PI", 
        "type": "Role"
      }
    ], 
    "sameAs": [
      "https://app.dimensions.ai/details/grant/grant.2410583"
    ], 
    "sdDataset": "grants", 
    "sdDatePublished": "2019-03-07T12:10", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/nih_projects_3.xml.gz", 
    "startDate": "2008-09-01T00:00:00Z", 
    "type": "MonetaryGrant", 
    "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=8315912"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.2410583'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.2410583'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.2410583'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.2410583'


 

This table displays all metadata directly associated to this object as RDF triples.

125 TRIPLES      19 PREDICATES      103 URIs      95 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:grant.2410583 schema:about anzsrc-for:2210
2 schema:amount N5f7828c8b1ff4f7187acabd77efc6706
3 schema:description DESCRIPTION (provided by applicant): This proposal describes a five-year training program to develop an academic career in Medical Genetics and gene therapy. The program will further advance the investigator's research in the development of an AAV-mediated gene targeting strategy for the treatment of Osteogenesis Imperfecta. The investigator will be mentored by Dr. David Russell, well recognized for his achievements in developing the adeno-associated virus (AAV) vector system for gene targeting. Osteogenesis Imperfecta (01) is a group of inherited collagen disorders characterized by bone fragility with clinical manifestations varying from a mild increase in fractures to severe bone deformities and death. Mutations that cause Ol are located in the COL1A1 and COL1A2 genes. Current treatment options are limited and do not alleviate the complications seen in Ol. Most gene therapy systems involve the process of gene addition, where a promoter and a gene are delivered into a cell and integrate randomly. In contrast, gene targeting uses homologous sequences to alter the cell's endogenous genes in a site specific manner. By this method mutated genes can be either knocked-out or corrected. The major advantage of gene targeting is that genes can be modified at their proper location on the chromosme without disrupting cellular gene regulation. Previous work by Dr. Russell has demonstrated that an AAV-mediated gene targeting vector can target the COL1A1 gene and disrupt dominant negative mutant procollagen production. It was shown that the loss of the mutant protein improved the processing, stability and structure of the collagen fibril. The objective of this proposal is to develop an AAV gene targeting vector that will target the COL1A2 gene, reduce random integration, and target multiple individuals with Ol. The specific aims include: 1) Develop an AAV gene-targeting vector to target the COL1A2 gene in Ol; 2) Develop an improved AAV gene-targeting vector to reduce the recovery of random integrants; and 3) Determine the effects of human variation on gene targeting. The completion of this project and the training received at the University of Washington will prepare the principle investigator to be a leading researcher in gene therapy.
4 schema:endDate 2013-12-31T00:00:00Z
5 schema:funder https://www.grid.ac/institutes/grid.420086.8
6 schema:identifier N9f8e0b6b94cd40e2be9e527b78bed328
7 Nba7e3140f7154b7ab7341e35ccf23135
8 schema:inLanguage en
9 schema:keywords AAV
10 AAV genes
11 AAV vectors
12 COL1A1
13 COL1A1 gene
14 COL1A2 gene
15 Dr. David Russell
16 Dr. Russell
17 METHODS
18 Medical Genetics
19 Most gene therapy systems
20 OBJECTIVE
21 OL
22 US
23 University
24 Washington
25 academic career
26 achievement
27 adeno
28 applicants
29 bone fragility
30 cells
31 cellular gene regulation
32 chromosmes
33 clinical manifestations
34 collagen disorders
35 collagen fibrils
36 completion
37 complications
38 contrast
39 current treatment options
40 death
41 description
42 development
43 dominant negative mutant procollagen production
44 effect
45 endogenous genes
46 five-year training program
47 fracture
48 gene addition
49 gene targeting
50 gene therapy
51 genes
52 groups
53 homologous sequences
54 human variation
55 improved AAV gene
56 investigator's research
57 investigators
58 loss
59 major advantage
60 mild increase
61 multiple individuals
62 mutant proteins
63 mutations
64 osteogenesis imperfecta
65 previous work
66 principle investigator
67 process
68 processing
69 program
70 project
71 promoter
72 proper location
73 proposal
74 random integrants
75 random integration
76 recovery
77 researchers
78 severe bone deformities
79 sites
80 specific aim
81 specific manner
82 stability
83 strategies
84 structure
85 training
86 treatment
87 vector
88 vector system
89 virus
90 schema:name Gene targeting with AAV vectors for the treatment of Osteogenesis Imperfecta
91 schema:recipient N831f46c248c94edb85213fcfe9854da4
92 sg:person.01202462577.23
93 https://www.grid.ac/institutes/grid.66875.3a
94 schema:sameAs https://app.dimensions.ai/details/grant/grant.2410583
95 schema:sdDatePublished 2019-03-07T12:10
96 schema:sdLicense https://scigraph.springernature.com/explorer/license/
97 schema:sdPublisher N2bfd38aa63094c848efb5d653ff3efee
98 schema:startDate 2008-09-01T00:00:00Z
99 schema:url http://projectreporter.nih.gov/project_info_description.cfm?aid=8315912
100 sgo:license sg:explorer/license/
101 sgo:sdDataset grants
102 rdf:type schema:MonetaryGrant
103 N2bfd38aa63094c848efb5d653ff3efee schema:name Springer Nature - SN SciGraph project
104 rdf:type schema:Organization
105 N5f7828c8b1ff4f7187acabd77efc6706 schema:currency USD
106 schema:value 657605
107 rdf:type schema:MonetaryAmount
108 N831f46c248c94edb85213fcfe9854da4 schema:member sg:person.01202462577.23
109 schema:roleName PI
110 rdf:type schema:Role
111 N9f8e0b6b94cd40e2be9e527b78bed328 schema:name dimensions_id
112 schema:value 2410583
113 rdf:type schema:PropertyValue
114 Nba7e3140f7154b7ab7341e35ccf23135 schema:name nih_id
115 schema:value K08AR053917
116 rdf:type schema:PropertyValue
117 anzsrc-for:2210 schema:inDefinedTermSet anzsrc-for:
118 rdf:type schema:DefinedTerm
119 sg:person.01202462577.23 schema:affiliation https://www.grid.ac/institutes/grid.66875.3a
120 schema:familyName DEYLE
121 schema:givenName DAVID R
122 rdf:type schema:Person
123 https://www.grid.ac/institutes/grid.420086.8 schema:Organization
124 https://www.grid.ac/institutes/grid.66875.3a schema:name MAYO CLINIC ROCHESTER
125 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...